Evidence map›Paper›PMID 37724635›Full record

ArticleHistology and histopathology2024

Prognostic impact of mitosis and necrosis in non-mucinous lung adenocarcinomas and correlation with IASLC grading system.

Gürdenız Serın, Pinar Savaş, İrem Şahver İşgör, Alı Özdıl, Alı Mizrak, Alı Veral, Denız Nart

Abstract read
PubMed Publisher
In one paragraph

Article in Histology and histopathology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Gürdenız SerınDepartment of Pathology, Ege University School of Medicine, Bornova, İzmir, Turkey. drgurdeniz@gmail.com.
Pinar SavaşDepartment of Pathology, Ege University School of Medicine, Bornova, İzmir, Turkey.
İrem Şahver İşgörDepartment of Pathology, Ege University School of Medicine, Bornova, İzmir, Turkey.
Alı ÖzdılDepartment of Thoracic Surgery, Ege University Faculty of Medicine, İzmir, Turkey.
Alı MizrakDepartment of Pathology, Ege University School of Medicine, Bornova, İzmir, Turkey.
Alı VeralDepartment of Pathology, Ege University School of Medicine, Bornova, İzmir, Turkey.
Denız NartDepartment of Pathology, Ege University School of Medicine, Bornova, İzmir, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn 2020, the International Lung Cancer Study Group (IASLC) Pathology Committee established a grading system for non-mucinous primary lung adenocarcinomas. This grading system is based on whether areas of high-grade patterns are present in more than 20% of the tumor. Parameters, such as necrosis, mitotic activity, lymphovascular invasion (LVI) and spread through air spaces (STAS), are excluded from evaluating the grading system.

methodsA total of 217 patients' lung resection materials for primary lung adenocarcinoma were re-reviewed using the IASLC grading system. Necrosis, mitotic activity, LVI status and STAS were also evaluated in the resection materials, aiming to demonstrate the relationship between these histopathological features and clinical outcome data.

resultsAt all stages, overall survival (OS) and recurrence-free survival (RFS) were related to grade (

conclusionsThe new grading system provides a highly efficient prognostic classification for survival. Necrosis and high mitotic count are important prognostic parameters for survival. Additionally, necrosis is a stage-independent prognostic factor for OS in grade 3 tumors, although no effect on prognosis can be demonstrated in grade 2 tumors.

Indexed as

Adenocarcinoma of LungLung NeoplasmsMitosisNecrosisNeoplasm GradingAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedPrognosisRetrospective Studies

Identifiers

PMID37724635

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.